AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.1 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Clinical Research | Open Access

Clinical features and prognosis of orbital inflammatory myofibroblastic tumor

Jing Li1Liang-Yuan Xu1Nan Wang1Rui Liu1Shan-Feng Zhao2Ting-Ting Ren1Qi-Han Guo1Bin Zhang3Hong Zhang4Hai-Han Yan1Yu-Fei Zhang1Jian-Min Ma1( )
Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing 100054, China
Department of Neurosurgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100054, China
Department of Ophthalmology, Shangdong Provincial Maternity and Child Care Hospital, Jinan 250014, Shandong Province, China
Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100054, China

Co-first Authors: Jing Li and Liang-Yuan Xu

Show Author Information

Abstract

AIM

To investigate the clinical features and prognosis of patients with orbital inflammatory myofibroblastic tumor (IMT).

METHODS

This retrospective study collected clinical data from 22 patients diagnosed with orbital IMT based on histopathological examination. The patients were followed up to assess their prognosis. Clinical data from patients, including age, gender, course of disease, past medical history, primary symptoms, ophthalmologic examination findings, general condition, as well as imaging, laboratory, histopathological, and immunohistochemical results from digital records were collected. Orbital magnetic resonance imaging (MRI) and(or) computed tomography (CT) scans were performed to assess bone destruction of the mass, invasion of surrounding tissues, and any inflammatory changes in periorbital areas.

RESULTS

The mean age of patients with orbital IMT was 28.24±3.30y, with a male-to-female ratio of 1.2:1. Main clinical manifestations were proptosis, blurred vision, palpable mass, and pain. Bone destruction and surrounding tissue invasion occurred in 72.73% and 54.55% of cases, respectively. Inflammatory changes in the periorbital site were observed in 77.27% of the patients. Hematoxylin and eosin staining showed proliferation of fibroblasts and myofibroblasts, accompanied by infiltration of lymphocytes and plasma cells. Immunohistochemical staining revealed that smooth muscle actin (SMA) and vimentin were positive in 100% of cases, while anaplastic lymphoma kinase (ALK) showed positivity in 47.37%. The recurrence rate of orbital IMT was 27.27%, and sarcomatous degeneration could occur. There were no significant correlations between recurrence and factors such as age, gender, laterality, duration of the disease, periorbital tissue invasion, bone destruction, periorbital inflammation, tumor size, fever, leukocytosis, or treatment (P>0.05). However, lymphadenopathy and a Ki-67 index of 10% or higher may be risk factors for recurrence (P=0.046; P=0.023).

CONCLUSION

Orbital IMT is a locally invasive disease that may recur or lead to sarcomatoid degeneration, primarily affecting young and middle-aged patients. The presence of lymphadenopathy and a Ki-67 index of 10% or higher may signify a poor prognosis.

References

【1】
【1】
 
 
International Journal of Ophthalmology
Pages 105-114

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Li J, Xu L-Y, Wang N, et al. Clinical features and prognosis of orbital inflammatory myofibroblastic tumor. International Journal of Ophthalmology, 2026, 19(1): 105-114. https://doi.org/10.18240/ijo.2026.01.14

515

Views

11

Downloads

1

Crossref

1

Web of Science

0

Scopus

0

CSCD

Received: 15 August 2024
Accepted: 20 August 2025
Published: 18 January 2026
© 2026 International Journal of Ophthalmology Press

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).